Genitourinary (GU) Cancer

Roche is leading the investigation of new options for patients suffering from genitourinary cancer, exploring the potential of cancer immunotherapy and treatment tailored to individuals.

ESMO 2019

Bladder Cancer: The Facts

Bladder cancer is one of several cancers associated with a high rate of mutations, which may be linked to a heightened immunogenicity. Learn more about the role of tumour-infiltrating immune cells and the pathways governing the immune response.

Learn more.